Paper Details

  1. Home
  2. Paper Details

Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer.

Author: AnderssonPatrik L, BegumAfshan, BrännströmKristoffer, IakovlevaIrina, NilssonLina, OlofssonAnders, Sauer-ErikssonA Elisabeth, WijsekeraAlexandra, ZhangJin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Tetrabromobisphenol A (TBBPA), a commonly used flame retardant, effectively stabilizes the tetrameric structure of transthyretin (TTR) with high selectivity in human plasma, offering potential as a drug scaffold for treating amyloid-related disorders.
Paper Details　
Original Abstract of the Article :
Amyloid formation of the human plasma protein transthyretin (TTR) is associated with several human disorders, including familial amyloidotic polyneuropathy (FAP) and senile systemic amyloidosis. Dissociation of TTR's native tetrameric assembly is the rate-limiting step in the conversion into amyloid...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836675/

データ提供：米国国立医学図書館（NLM）

Tetrabromobisphenol A: A Potential Treatment for Amyloid Diseases

Amyloid diseases, such as familial amyloidotic polyneuropathy (FAP), are caused by the misfolding of proteins into harmful amyloid fibrils. This research investigates the potential of tetrabromobisphenol A (TBBPA), a common flame retardant, as a stabilizer of transthyretin (TTR), a protein associated with amyloid formation.

TBBPA Shows Promise in Stabilizing Transthyretin

The study found that TBBPA efficiently stabilizes the tetrameric structure of TTR, preventing its misfolding and amyloid formation. This effect is comparable to the approved drug tafamidis and even surpasses the efficacy of diflunisal, both of which are used for FAP treatment. This finding suggests that TBBPA could potentially be a valuable therapeutic agent for amyloid diseases.

A New Avenue for Treating Amyloid Diseases

The research highlights the potential of TBBPA as a novel therapeutic agent for amyloid diseases. Its ability to stabilize TTR and prevent amyloid formation offers a promising approach to managing these debilitating disorders. Further research is needed to fully evaluate its safety and efficacy in humans before it can be used clinically.

Dr. Camel's Conclusion

The discovery of TBBPA's potential for treating amyloid diseases is a significant breakthrough. Just as a camel relies on its hump to store energy for survival, we must continue to explore new strategies for overcoming these challenging diseases. This research offers a promising avenue for developing effective therapies for amyloid diseases, providing hope for those affected.

Date :
  1. Date Completed 2016-08-29
  2. Date Revised 2019-02-19
Further Info :

Pubmed ID

27093678

DOI: Digital Object Identifier

PMC4836675

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.